These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 35625189)
21. Antimicrobial activity of ceftazidime/avibactam, ceftolozane/tazobactam and comparator agents against Sader HS; Duncan LR; Doyle TB; Castanheira M JAC Antimicrob Resist; 2021 Sep; 3(3):dlab126. PubMed ID: 34514403 [TBL] [Abstract][Full Text] [Related]
22. Antimicrobial activity of ceftazidime-avibactam and comparators against Pseudomonas aeruginosa and Enterobacterales collected in Croatia, Czech Republic, Hungary, Poland, Latvia and Lithuania: ATLAS Surveillance Program, 2019. Adámková V; Mareković I; Szabó J; Pojnar L; Billová S; Horvat Herceg S; Kuraieva A; Możejko-Pastewka B Eur J Clin Microbiol Infect Dis; 2022 Jun; 41(6):989-996. PubMed ID: 35596097 [TBL] [Abstract][Full Text] [Related]
23. In vitro activity of ceftazidime/avibactam against isolates of carbapenem-non-susceptible Enterobacteriaceae collected during the INFORM global surveillance programme (2015-17). Spiliopoulou I; Kazmierczak K; Stone GG J Antimicrob Chemother; 2020 Feb; 75(2):384-391. PubMed ID: 31742604 [TBL] [Abstract][Full Text] [Related]
24. Borde K; Kareem MA; Sharma RM; Dass SM; Ravi V; Mathai D Microbiol Spectr; 2023 Sep; 11(5):e0084723. PubMed ID: 37737637 [TBL] [Abstract][Full Text] [Related]
25. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States. Sader HS; Huband MD; Castanheira M; Flamm RK Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652 [No Abstract] [Full Text] [Related]
26. In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program. Jia P; Zhu Y; Zhang H; Cheng B; Guo P; Xu Y; Yang Q BMC Microbiol; 2022 Oct; 22(1):234. PubMed ID: 36182895 [TBL] [Abstract][Full Text] [Related]
27. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. Sader HS; Castanheira M; Flamm RK; Mendes RE; Farrell DJ; Jones RN Int J Antimicrob Agents; 2015 Jul; 46(1):53-9. PubMed ID: 25956844 [TBL] [Abstract][Full Text] [Related]
28. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199 [TBL] [Abstract][Full Text] [Related]
35. In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates. Meletiadis J; Paranos P; Georgiou PC; Vourli S; Antonopoulou S; Michelaki A; Vagiakou E; Pournaras S Int J Antimicrob Agents; 2021 Nov; 58(5):106440. PubMed ID: 34551356 [TBL] [Abstract][Full Text] [Related]
36. Ceftolozane-tazobactam and ceftazidime-avibactam activity against β-lactam-resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Enterobacterales clinical isolates from U.S. medical centres. Hirsch EB; Brigman HV; Zucchi PC; Chen A; Anderson JC; Eliopoulos GM; Cheung N; Gilbertsen A; Hunter RC; Emery CL; Bias TE J Glob Antimicrob Resist; 2020 Sep; 22():689-694. PubMed ID: 32353524 [TBL] [Abstract][Full Text] [Related]
37. Ceftazidime-Avibactam Antimicrobial Activity and Spectrum When Tested Against Gram-negative Organisms From Pediatric Patients: Results From the INFORM Surveillance Program (United States, 2011-2015). Sader HS; Huband MD; Duncan LR; Flamm RK Pediatr Infect Dis J; 2018 Jun; 37(6):549-554. PubMed ID: 29206750 [TBL] [Abstract][Full Text] [Related]
38. Assessment of Ceftazidime-Avibactam 30/20-μg Disk, Etest versus Broth Microdilution Results When Tested against Han R; Yang X; Yang Y; Guo Y; Yin D; Ding L; Wu S; Zhu D; Hu F Microbiol Spectr; 2022 Feb; 10(1):e0109221. PubMed ID: 35019685 [TBL] [Abstract][Full Text] [Related]
39. Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. Sader HS; Carvalhaes CG; Arends SJR; Castanheira M; Mendes RE J Antimicrob Chemother; 2021 Feb; 76(3):659-666. PubMed ID: 33276387 [TBL] [Abstract][Full Text] [Related]
40. Antimicrobial activity of cephalosporin-beta-lactamase inhibitor combinations against drug-susceptible and drug-resistant Alnimr AM; Alamri AM J Taibah Univ Med Sci; 2020 Jun; 15(3):203-210. PubMed ID: 32647515 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]